Your search returned 2 studies. (Get alerts for new studies):
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Conditions: NHL - Lymphoma, Non-Hodgkin - Lymphoma, B-Cell - Lymphoma, Follicular - Lymphoma, Intermediate-Grade - Lymphoma, Large-Cell - Lymphoma, Low-Grade - Lymphoma, Mixed-Cell - Lymphoma, Small-Cell - Leukemia, Lymphocytic, Chronic - Leukemia, B-Cell, Chronic - 4 Locations available
- A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Conditions: Advanced Malignancies - Carcinoma, Non-Small-Cell Lung - Anaplastic Large Cell Lymphoma - Diffuse Large Cell Lymphoma - Inflammatory Myofibroblastic Tumors 6 Locations available
|